427 related articles for article (PubMed ID: 28073785)
1. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma.
Merryman RW; Kim HT; Zinzani PL; Carlo-Stella C; Ansell SM; Perales MA; Avigdor A; Halwani AS; Houot R; Marchand T; Dhedin N; Lescaut W; Thiebaut-Bertrand A; François S; Stamatoullas-Bastard A; Rohrlich PS; Labussière Wallet H; Castagna L; Santoro A; Bachanova V; Bresler SC; Srivastava A; Kim H; Pesek E; Chammas M; Reynolds C; Ho VT; Antin JH; Ritz J; Soiffer RJ; Armand P
Blood; 2017 Mar; 129(10):1380-1388. PubMed ID: 28073785
[TBL] [Abstract][Full Text] [Related]
2. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.
Haverkos BM; Abbott D; Hamadani M; Armand P; Flowers ME; Merryman R; Kamdar M; Kanate AS; Saad A; Mehta A; Ganguly S; Fenske TS; Hari P; Lowsky R; Andritsos L; Jagasia M; Bashey A; Brown S; Bachanova V; Stephens D; Mineishi S; Nakamura R; Chen YB; Blazar BR; Gutman J; Devine SM
Blood; 2017 Jul; 130(2):221-228. PubMed ID: 28468799
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study.
Ito A; Kim SW; Matsuoka KI; Kawakita T; Tanaka T; Inamoto Y; Toubai T; Fujiwara SI; Fukaya M; Kondo T; Sugita J; Nara M; Katsuoka Y; Imai Y; Nakazawa H; Kawashima I; Sakai R; Ishii A; Onizuka M; Takemura T; Terakura S; Iida H; Nakamae M; Higuchi K; Tamura S; Yoshioka S; Togitani K; Kawano N; Suzuki R; Suzumiya J; Izutsu K; Teshima T; Fukuda T
Int J Hematol; 2020 Nov; 112(5):674-689. PubMed ID: 32748216
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.
Merryman RW; Castagna L; Giordano L; Ho VT; Corradini P; Guidetti A; Casadei B; Bond DA; Jaglowski S; Spinner MA; Arai S; Lowsky R; Shah GL; Perales MA; De Colella JMS; Blaise D; Herrera AF; Shouse G; Spilleboudt C; Ansell SM; Nieto Y; Badar T; Hamadani M; Feldman TA; Dahncke L; Singh AK; McGuirk JP; Nishihori T; Chavez J; Serritella AV; Kline J; Mohty M; Dulery R; Stamatoulas A; Houot R; Manson G; Moles-Moreau MP; Orvain C; Bouabdallah K; Modi D; Ramchandren R; Lekakis L; Beitinjaneh A; Frigault MJ; Chen YB; Lynch RC; Smith SD; Rao U; Byrne M; Romancik JT; Cohen JB; Nathan S; Phillips T; Joyce RM; Rahimian M; Bashey A; Ballard HJ; Svoboda J; Torri V; Sollini M; De Philippis C; Magagnoli M; Santoro A; Armand P; Zinzani PL; Carlo-Stella C
Leukemia; 2021 Sep; 35(9):2672-2683. PubMed ID: 33658659
[TBL] [Abstract][Full Text] [Related]
5. PD-1 blockade induces remissions in relapsed classical Hodgkin lymphoma following allogeneic hematopoietic stem cell transplantation.
Godfrey J; Bishop MR; Syed S; Hyjek E; Kline J
J Immunother Cancer; 2017; 5():11. PubMed ID: 28239465
[TBL] [Abstract][Full Text] [Related]
6. A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation.
Davids MS; Kim HT; Costello C; Herrera AF; Locke FL; Maegawa RO; Savell A; Mazzeo M; Anderson A; Boardman AP; Weber A; Avigan D; Chen YB; Nikiforow S; Ho VT; Cutler C; Alyea EP; Bachireddy P; Wu CJ; Ritz J; Streicher H; Ball ED; Bashey A; Soiffer RJ; Armand P
Blood; 2020 Jun; 135(24):2182-2191. PubMed ID: 32478814
[TBL] [Abstract][Full Text] [Related]
7. Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies.
Brierley CK; Jones FM; Hanlon K; Peniket AJ; Hatton C; Collins GP; Schuh A; Medd P; Clark A; Ward J; Chaganti S; Malladi R; Parker A; Craddock C; Danby R; Rocha V
Br J Haematol; 2019 Feb; 184(4):547-557. PubMed ID: 30467838
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
[TBL] [Abstract][Full Text] [Related]
9. T-cell-depleted allogeneic transplant without donor leukocyte infusions results in excellent long-term survival in patients with multiply relapsed Lymphoma. Predictors for survival after transplant relapse.
Kenkre VP; Horowitz S; Artz AS; Liao C; Cohen KS; Godley LA; Kline JP; Smith SM; Stock W; van Besien K
Leuk Lymphoma; 2011 Feb; 52(2):214-22. PubMed ID: 21142785
[TBL] [Abstract][Full Text] [Related]
10. Risk factors predicting graft-versus-host disease and relapse-free survival after allogeneic hematopoietic stem cell transplantation in relapsed or refractory non-Hodgkin's lymphoma.
Jeon YW; Yoon S; Min GJ; Park SS; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Lee JW; Cho SG
Ann Hematol; 2019 Jul; 98(7):1743-1753. PubMed ID: 31089793
[TBL] [Abstract][Full Text] [Related]
11. Impact of very early CD4(+) /CD8(+) T cell counts on the occurrence of acute graft-versus-host disease and NK cell counts on outcome after pediatric allogeneic hematopoietic stem cell transplantation.
Huttunen P; Taskinen M; Siitonen S; Saarinen-Pihkala UM
Pediatr Blood Cancer; 2015 Mar; 62(3):522-8. PubMed ID: 25417898
[TBL] [Abstract][Full Text] [Related]
12. Mogamulizumab Treatment Prior to Allogeneic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-versus-Host Disease.
Sugio T; Kato K; Aoki T; Ohta T; Saito N; Yoshida S; Kawano I; Henzan H; Kadowaki M; Takase K; Muta T; Miyawaki K; Yamauchi T; Shima T; Takashima S; Mori Y; Yoshimoto G; Kamezaki K; Takenaka K; Iwasaki H; Ogawa R; Ohno Y; Eto T; Kamimura T; Miyamoto T; Akashi K
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1608-1614. PubMed ID: 27220263
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma.
Herbaux C; Gauthier J; Brice P; Drumez E; Ysebaert L; Doyen H; Fornecker L; Bouabdallah K; Manson G; Ghesquières H; Tabrizi R; Hermet E; Lazarovici J; Thiebaut-Bertrand A; Chauchet A; Demarquette H; Boyle E; Houot R; Yakoub-Agha I; Morschhauser F
Blood; 2017 May; 129(18):2471-2478. PubMed ID: 28270452
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Minimal Residual Disease and Graft-versus-Host Disease-Guided Multiple DLIs Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia.
Yan CH; Liu QF; Wu DP; Zhang X; Xu LP; Zhang XH; Wang Y; Huang H; Bai H; Huang F; Ma X; Huang XJ
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1311-1319. PubMed ID: 28483716
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Younes A; Santoro A; Shipp M; Zinzani PL; Timmerman JM; Ansell S; Armand P; Fanale M; Ratanatharathorn V; Kuruvilla J; Cohen JB; Collins G; Savage KJ; Trneny M; Kato K; Farsaci B; Parker SM; Rodig S; Roemer MG; Ligon AH; Engert A
Lancet Oncol; 2016 Sep; 17(9):1283-94. PubMed ID: 27451390
[TBL] [Abstract][Full Text] [Related]
16. Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.
Barta SK; Zain J; MacFarlane AW; Smith SM; Ruan J; Fung HC; Tan CR; Yang Y; Alpaugh RK; Dulaimi E; Ross EA; Campbell KS; Khan N; Siddharta R; Fowler NH; Fisher RI; Oki Y
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):356-364.e3. PubMed ID: 31029646
[TBL] [Abstract][Full Text] [Related]
17. Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality.
Fuji S; Inoue Y; Utsunomiya A; Moriuchi Y; Uchimaru K; Choi I; Otsuka E; Henzan H; Kato K; Tomoyose T; Yamamoto H; Kurosawa S; Matsuoka K; Yamaguchi T; Fukuda T
J Clin Oncol; 2016 Oct; 34(28):3426-33. PubMed ID: 27507878
[TBL] [Abstract][Full Text] [Related]
18. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial.
Armand P; Nagler A; Weller EA; Devine SM; Avigan DE; Chen YB; Kaminski MS; Holland HK; Winter JN; Mason JR; Fay JW; Rizzieri DA; Hosing CM; Ball ED; Uberti JP; Lazarus HM; Mapara MY; Gregory SA; Timmerman JM; Andorsky D; Or R; Waller EK; Rotem-Yehudar R; Gordon LI
J Clin Oncol; 2013 Nov; 31(33):4199-206. PubMed ID: 24127452
[TBL] [Abstract][Full Text] [Related]
19. Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation.
Ijaz A; Khan AY; Malik SU; Faridi W; Fraz MA; Usman M; Tariq MJ; Durer S; Durer C; Russ A; Parr NNC; Baig Z; Sagar F; Ali Z; McBride A; Anwer F
Biol Blood Marrow Transplant; 2019 Jan; 25(1):94-99. PubMed ID: 30195074
[TBL] [Abstract][Full Text] [Related]
20. Potential Role of the PD-1/PD-L1 Axis in the Immune Regulation of Chronic GVHD.
Klobuch S; Weber D; Holler B; Herr W; Holler E; Wolff D
Oncol Res Treat; 2017; 40(7-8):447-450. PubMed ID: 28683452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
